Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…
Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously
On Jun. 14, 2021, Novavax announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax,…
Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccine
On Jun. 11, 2021, Novavax announced preclinical and clinical data on the company’s original recombinant protein COVID-19 vaccine…
NIH launched clinical trial of universal influenza vaccine candidate
On Jun. 1, 2021, a first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle…
Novavax announced MOU to explore expansion of COVID-19 vaccine activities in South Korea
On May 22, 2021, Novavax announced the signing of a non-binding memorandum of understanding (MoU) with the Ministry…
Complete trial results of Novavax COVID-19 investigational vaccine posted to preprint server medRxiv
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
Novavax announced participation in mix-and-match COVID-19 vaccine booster trial in the United Kingdom
On May 21, 2021, Novavax announced participation in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that led…
Novavax announced positive preclinical data for combination influenza and COVID-19 vaccine candidate
On May 10, 2021, Novavax announced data from a preclinical study of the company’s combination quadrivalent seasonal flu…
Novavax and Gavi executed advance purchase agreement for COVID-19 vaccine for COVAX facility
On May 6, 2021, Novavax announced that it had finalized an advance purchase agreement (APA) with Gavi, the…
NEJM published phase 2b clinical trial results demonstrating efficacy of COVID-19 vaccine against B.1.351 variant
On May 5, 2021, Novavax announced the publication of results from the initial primary analysis of a Phase…
Novavax initiated pediatric expansion for phase 3 clinical trial of COVID-19 vaccine
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
COVID-19 vaccine responses studied in people with immune deficits
On Apr. 23, 2021, the NIH announced that a study assessing how people with immune system deficiencies or…
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
Positive topline data showed Fostamatinib met primary endpoint of safety in phase 2 clinical trial in hospitalized COVID-19 patients
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
GSK to manufacture Novavax’ COVID-19 vaccine
On Mar. 29, 2021, Novavax, GSK and the UK Government Vaccines Taskforce announced an agreement in principle to…
Rigel announced completion of patient enrollment for phase 2 trial of fostamatinib in hospitalized COVID-19 patients
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
Novavax confirmed ligh levels of efficacy against original and variant COVID-19 strains in UK and South Africa trials
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
Novavax completed enrollment of PREVENT-19, COVID-19 vaccine pivotal phase 3 trial in the US and Mexico
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
Novavax announced MOU with Gavi for cumulative supply to COVAX facility of 11 billion doses of COVID-19 vaccine
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
Novavax announced expanded agreement with SK Bioscience for 40 million doses of COVID-19 vaccine for South Korea
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
Novavax and Government of Switzerland announced agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…